Key facts
- This page summarizes Catalyst4, Inc.'s Form 4 filing for MapLight Therapeutics, Inc. (MPLT).
- 4 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jul 2026, 18:39.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Purchase
Purchase
Purchase
Purchase
Additional SEC filing notes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $10.295 to $11.28, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4.
Footnote F2
The shares are held of record by Catalyst4, Inc. ("Catalyst4"). As the members of the board of directors of Catalyst4, Robert Brown, Ekemini Riley and Mark Vorsatz share voting and dispositive power with respect to the shares held by Catalyst4. Each of Mr. Brown, Ms. Riley and Mr. Vorsatz disclaims beneficial ownership of the shares reported herein.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.31 to $12.00, inclusive.